World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
106
Citations
39812
World Ranking
1152
National Ranking
685

Medicine

D-Index
107
Citations
40022
World Ranking
6288
National Ranking
3354

Overview

Irwin D. Bernstein is affiliated with the Fred Hutchinson Cancer Research Center in the United States. Their research spans multiple fields, with a significant focus on medicine and biochemistry, genetics, and molecular biology. They have contributed to molecular biology, hematology, immunology, cell biology, and genetics as subfields of study.

Their main scientific topics include:

  • Single-cell and spatial transcriptomics
  • Zebrafish biomedical research applications
  • Hematopoietic stem cell transplantation
  • Acute myeloid leukemia research
  • Immune cells in cancer
  • CAR-T cell therapy research
  • Renal and related cancers

Bernstein has published frequently in several scientific journals. The principal venues for their work include bioRxiv (Cold Spring Harbor Laboratory), Blood, Experimental Hematology, Cell Reports, and the Journal of Clinical Investigation.

Frequent coauthors collaborating with Bernstein include Brandon Hadland, Barbara Varnum-Finney, Stacey Dozono, Cynthia Nourigat-Mckay, and Shahin Rafii.

Some of the recent publications authored or co-authored by Bernstein are:

  • Multipotent progenitors and hematopoietic stem cells arise independently from hemogenic endothelium in the mouse embryo, 2021, Cell Reports
  • Engineering a niche supporting hematopoietic stem cell development using integrated single-cell transcriptomics, 2022, Nature Communications
  • CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target, 2022, Journal of Clinical Investigation
  • NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness, 2022, Blood
  • Notch blockade overcomes endothelial cell-mediated resistance of FLT3/ITD-positive AML progenitors to AC220 treatment, 2020, Leukemia

Bernstein's work includes contributions to understanding hematopoietic stem cell biology, acute myeloid leukemia, and immune cell functions related to cancer. The research leverages advanced methodologies such as single-cell transcriptomics to investigate stem cell niches and immune interactions. Their studies on CAR-T cell therapy targets and the molecular mechanisms of leukemia highlight intersections between cancer biology and immunotherapy.

Best Publications

  • Leukocyte typing II

    Ellis L. Reinherz;Barton F. Haynes;Lee M. Nadler;Irwin D. Bernstein

  • Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

    Eric L. Sievers;Richard A. Larson;Edward A. Stadtmauer;Elihu Estey

  • Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution

    Colleen Delaney;Shelly Heimfeld;Carolyn Brashem-Stein;Howard Voorhies

  • Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling.

    Barbara Varnum-Finney;Lanwei Xu;Carolyn Brashem-Stein;Cynthia Nourigat

  • Antigen CD34+ marrow cells engraft lethally irradiated baboons.

    R J Berenson;R G Andrews;W I Bensinger;D Kalamasz

  • Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

    Oliver W. Press;Janet F. Eary;Frederick R. Appelbaum;Paul J. Martin

  • Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma.

    RJ Berenson;WI Bensinger;RS Hill;RG Andrews

  • Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

    Philip R. Hamann;Lois M. Hinman;Irwin Hollander;Carl F. Beyer

  • Endothelial Cells Are Essential for the Self-Renewal and Repopulation of Notch-Dependent Hematopoietic Stem Cells

    Jason M. Butler;Daniel J. Nolan;Eva L. Vertes;Barbara Varnum-Finney

  • Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.

    E.L. Sievers;F.R. Appelbaum;R.T. Spielberger;S.J. Forman

  • Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

    Soheil Meshinchi;William G. Woods;Derek L. Stirewalt;David A. Sweetser

  • Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties.

    R G Andrews;J W Singer;I D Bernstein

  • The SmoA1 Mouse Model Reveals That Notch Signaling Is Critical for the Growth and Survival of Sonic Hedgehog-Induced Medulloblastomas

    Andrew R. Hallahan;Joel I. Pritchard;Stacey Hansen;Mark Benson

  • Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas

    O.W Press;O.W Press;F Appelbaum;F Appelbaum;P.J Martin;P.J Martin;D.C Matthews;D.C Matthews

  • Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors

    Robert G. Andrews;Jack W. Singer;Irwin D. Bernstein

  • SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

    May S. Kung Sutherland;Roland B. Walter;Scott C. Jeffrey;Patrick J. Burke

  • Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

    Richard A. Larson;Eric L. Sievers;Eric L. Sievers;Edward A. Stadtmauer;Bob Löwenberg

  • Immunotherapy of Cancer: Regression of Intradermal Tumors and Prevention of Growth of Lymph Node Metastases After Intralesional Injection of Living Mycobacterium bovis

    Berton Zbar;Irwin D. Bernstein;Gerald L. Bartlett;Michael G. Hanna

  • Recombinant human stem cell factor enhances the formation of colonies by CD34+ and CD34+lin- cells, and the generation of colony-forming cell progeny from CD34+lin- cells cultured with interleukin-3, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor.

    Irwin D. Bernstein;Robert G. Andrews;Krisztina M. Zsebo

  • Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.

    Vincent H. J. van der Velden;Jeroen G. te Marvelde;Patricia G. Hoogeveen;Irwin D. Bernstein

Frequent Co-Authors

Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center
Oliver W. Press
Oliver W. Press University of Washington
Todd A. Alonzo
Todd A. Alonzo University of Southern California
Paul J. Martin
Paul J. Martin Fred Hutchinson Cancer Research Center
Jerald P. Radich
Jerald P. Radich Fred Hutchinson Cancer Research Center
Betsy A. Hirsch
Betsy A. Hirsch University of Minnesota
Susana C. Raimondi
Susana C. Raimondi St. Jude Children's Research Hospital
Michael R. Loken
Michael R. Loken Fred Hutchinson Cancer Research Center
Shahin Rafii
Shahin Rafii Cornell University
William G. Woods
William G. Woods Emory University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Irwin D. Bernstein

Trending Scientists